ACNS1831: A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

Go Back to All Clinical Trials

ACNS1831: A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Newly Diagnosed Or Previously Untreated Neurofibromatosis Type 1 (nf1) Associated Low-grade Glioma (lgg)
Age: Between 2 Year(s) - 21 Year(s)
Gender: Male or Female

Other Inclusion Criteria:

1) Patients must have Neurofibromatosis Type 1 (NF1) based on clinical criteria. 2) Patients must be newly diagnosed or have previously diagnosed NF-1 associated LGG that has not been treated with any modality other than surgery.

You may not be eligible for this study if the following are true:

1) Patients with a concurrent malignancy or history of treatment (other than surgery) for another tumor within the last year are ineligible. 2) Received any prior tumor-directed therapy including chemotherapy, radiation therapy, immunotherapy, or bone marrow transplant.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies